shenzhen salubris pharmaceuticals co., ltd. (salubris) is a comprehensive pharmaceutical company that integrates pharmaceutical products research and development, production and business sales, founded in 1998 and headquartered in shenzhen, china.
more
the company business focuses in the therapeutic fields of cardiovascular, anti-diabetic, antineoplastic and orthopedic, as well as three mainlines of the high-end chemical medicine, innovative biological medicines and medical apparatus and instruments, forming the strategic synergy between products. in the cardiovascular field, the key products are all innovative.
as a patient-first pharmaceutical company, we have accumulated rich expertise and resources in the field of small molecule, biological molecules and medical devices. in the next 2-3 years, we will rapidly diversify the product line of chemical pharmaceuticals. furthermore, we have completed the middle-term and long-term products planning of the innovative biological medicines, laying a foundation for the company to become an excellent biological enterprise.
for latest news and events.
salubris discloses accurate company information completely and treats all investors in a fair and transparent manner to promote the communication as well as the sincere and harmonious relationship building with investors. we are looking forward to realizing the strategic target of the company and achieving win-win cooperation with investors.
we are looking forward to long and successful partnership with leading academic institutions, biotech companies and pharma companies in the areas of cardiovascular, metabolic disease and cancer. we are seeking cooperation for both pre-clinical and clinical development.
at salubris, we believe that our employees are the foundation for our success. we share our passion for improving the lives of patients and the health of societies around the world.
2008-2017,以新医改为始点,中国医药产业经历了特质鲜明的十年发展:政策、经济、社会、技术等各方面因素都发生了前所未有的变化,可以说,过往十年,是传统模式逐渐走向终结的十年,也是催生新生态的十年。
为什么短期内就有如此多的医疗器械企业消失?笔者认为,除了医疗器械企业自身因素外,与国家诸多相关行业的政策变化也有着很大关系。
关于《改革完善短缺药品供应保障机制的实施意见》解读